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Background: Sex hormone-binding globulin (SHBG) levels and sex hormones have been implicated in the
pathogenesis of type 2 diabetes and cardiovascular diseases. As fatty liver has been suggested to be a major
determinant of SHBG levels, we examined whether the associations of SHBG and testosterone with diabetes were
independent of fatty liver.
Methods: We conducted a case–control study that included 300 diabetes cases (215 men and 85 women) and
300 matched controls from the Saku cohort study. Diabetes was defined by either fasting plasma glucose levels
≥126 mg/dL, 2-h post-load glucose levels ≥200 mg/dL after a 75 g oral glucose tolerance test, or diabetes
diagnosed by physicians. We fitted conditional logistic regression models to examine the associations between
SHBG and total testosterone levels with diabetes by sex. To evaluate the impact of fatty liver, we used the fatty liver
index (FLI), a validated measure derived from serum triglyceride levels, body mass index (BMI), waist circumference,
and γ-glutamyltransferase levels.
Results: After adjusting for age, family history of diabetes, smoking, physical activity, BMI, and FLI, SHBG levels were
inversely associated with diabetes among women (odds ratio [OR] comparing the highest with the lowest quartiles,
0.13 [95% confidence interval {CI}, 0.02–0.96]), but not among men. Similar patterns were observed in a subgroup
analysis restricted to postmenopausal women"(OR, 0.12 [95% CI, 0.01–1.17]). In contrast, testosterone levels were
inversely associated with diabetes among men (OR, 0.45 [95% CI, 0.23–0.89]), but not among women.
Conclusions: Our findings suggest that SHBG in women and testosterone in men may be inversely associated
with diabetes.
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Emerging data indicate that sex hormone-binding globu-
lin (SHBG) as well as adipose tissue function may play
important roles in the development of type 2 diabetes
[1-3] and cardiovascular diseases [4,5]. SHBG is synthe-
sized primarily in the liver and binds to androgens and* Correspondence: mnoda@hosp.ncgm.go.jp
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reproduction in any medium, provided the orestrogens, thereby regulating the biologically active frac-
tion of sex hormones [6]. Thus, the circulating SHBG
level is a major determinant of the metabolic clearance
of sex hormones, modulating the access of such sex hor-
mones to their target tissues. The plasma membranes of
various kinds of cells have been recently shown to be
capable of binding specifically and with a high affinity to
SHBG, mediating sex hormone signaling at the cell
membrane through SHBG receptors [7,8].
Recent molecular epidemiologic studies mainly from
Western populations have reported that geneticallyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Goto et al. Cardiovascular Diabetology 2012, 11:130 Page 2 of 9
http://www.cardiab.com/content/11/1/130determined levels of SHBG were inversely associated
with type 2 diabetes risk [2,9], lending support to the
roles of SHBG in the development of type 2 diabetes.
Importantly, fatty liver has been recently suggested to be
a major determinant of decreased SHBG levels [10]. Be-
cause fatty liver is a strong risk factor of type 2 diabetes
[11], investigating whether fatty liver accounts for the
SHBG and type 2 diabetes relation may provide further
insight into the role of SHBG in the pathogenesis of type
2 diabetes. However, the impact of liver function on the
association has not been studied yet. Moreover, the pre-
vious studies examining the relation between SHBG and
type 2 diabetes are mainly from European populations.
In addition, a sexually-dimorphic relationship between
total testosterone levels and type 2 diabetes has been
suggested. Studies in rodents reported that male andro-
gen receptor knockout mice manifested late onset obes-
ity with increased lipogenesis, insulin resistance, and
impaired glucose tolerance [12-14], while obesity did not
develop in the female androgen receptor knockout mice
[14]. Further, a systematic review and meta-analysis
reported that lower testosterone levels are associated
with diabetes in men, whilst higher testosterone levels
are associated with diabetes in women [1].
The purpose of this study was 1) to examine the asso-
ciations of SHBG and testosterone with type 2 diabetes
by sex among a Japanese population, independent of
traditional diabetes risk factors, if such associations exist,
2) to evaluate whether the associations are independent
of the fatty liver index (FLI), a validated measure of fatty
liver, and 3) to examine whether sexual-dimorphism
exists in the associations.
Methods
Study population
This was a cross-sectional analysis of the Saku cohort,
which was launched from 2009 in Saku Central Hospital
Human Dock Center in Saku city, Nagano Prefecture,
Japan. Participants who visited for a health checkup be-
tween May 5, 2009 to September 30, 2010, and who
agreed to participate in the cohort were included in the
study. From the study population at baseline (n = 2,565),
we excluded subjects with missing data (n = 30), age
< 50 years old (n = 350), and age ≥ 80 (n = 16). Of the
remaining 2,169 participants, 301 participants were
defined to have diabetes. According to the WHO criteria
[15], diabetes was defined by either fasting plasma glu-
cose levels ≥126 mg/dL, 2-h post-load glucose levels
≥200 mg/dL after a 75 g oral glucose tolerance test, or
diabetes diagnosed by physicians. Of the remaining
1,868 participants, 542 participants who were defined
to have impaired glucose tolerance or impaired fasting
glucose according to the WHO criteria were excluded.
Control participants were randomly selected from theremaining 1,326 participants and individually matched
to cases on age and sex (n = 301). Of these 602 parti-
cipants, 1 case–control pair was excluded from the
analysis because of no remaining serum sample for 1
male case, leaving 300 diabetes cases and 300 matched
controls in the analysis. This study was reviewed and
approved by the Ethical Committee of the National In-
stitute of Health and Nutrition and Saku Central Hos-
pital. Participants received a precise explanation of the
study and provided their written informed consent.
Anthropometric measurements
The height (cm) and weight (kg) of the subjects were
measured with an automatic scale (Tanita, BF-220,
Tokyo, Japan), in light clothing. The body mass index
(BMI) was calculated as the weight (kg) divided by the
squared height (m2). Waist circumference was measured
twice at the umbilicus level while the subject was in a
standing position using a fiberglass measuring tape; the
average measurement was used for the analysis. Blood
pressure was measured while the subject was in a sitting
position using a validated automated blood pressure
monitor (ES-H55; Terumo, Tokyo, Japan). The physical
activity levels were obtained by asking the participants
about their average frequency of physical activity: rarely/
never, 1 to 3 times per month, 1 to 2 times per week,
and more than 3 times per week.
Laboratory procedures
Following an overnight fast, blood samples were col-
lected at the time of each health checkup at the Saku
Health Dock Center. Blood samples were collected in
tubes containing EDTA and heparin for the measure-
ment of the fasting plasma glucose, insulin, and HbA1c
levels, and the remaining frozen serum samples were
sent to the laboratory at the National Institute for
Health and Nutrition and were stored in deep freezers.
Serum gel separator tubes were used for the measure-
ment of the total cholesterol, HDL cholesterol, and tri-
glyceride (TG) levels. Routine laboratory blood analyses
were performed at the Saku Central Hospital. HbA1c
levels were measured using a high-performance liquid
chromatography method (TOSOH HLC-723 G8; Tosoh
Corporation, Tokyo, Japan), with intra- and inter-assay
coefficients of variation (CVs) of 0.5–1.4% and 0.6–1.3%,
respectively. The plasma glucose levels were analyzed
using an enzymatic method (ECO glucose buffer; A&T
Corporation, Kanagawa, Japan), with intra- and inter-
assay CVs of 0.3–0.5% and 0.6–0.8%, respectively. The
plasma insulin levels were analyzed using an electroche-
miluminescence immunoassay (Modular E170; Roche
Diagnostics, Mannheim, Germany), with intra- and
inter-assay CVs of 0.5–2.0% and 3.2–3.6%, respectively.
The serum albumin levels were measured with a
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ALB Test Kit; KAINOS Laboratories Inc., Tokyo, Japan),
intra- and inter-assay CVs of 1.2–2.2% and 1.7–2.4%, re-
spectively. The serum γ-glutamyl-transferase (GGT)
levels were analyzed with the Japan Society of Clinical
Chemistry reference method (Cica Liquid γ-GT J; Kanto
Chemical Co, Tokyo, Japan) and an autoanalyzer BM-
2250 (Nihon Denshi, Tokyo, Japan), with intra- and
inter-assay CVs of 1.0–3.7% and 0.96–3.65%, respect-
ively. The serum total cholesterol, HDL cholesterol, and
TG concentrations were determined using enzymatic
methods (serum total cholesterol: Detaminar L TC II,
Kyowa Medex, Tokyo, Japan; HDL cholesterol: Cholest-
est N HDL,Sekisui Medical Co. Ltd., Tokyo, Japan; and
TG concentrations: Mizuho TG-FR Type II, Mizuho
Medi, Saga, Japan) and an autoanalyzer BM-2250 (Nihon
Denshi, Tokyo, Japan), with intra- and inter-assay CVs of
≤ 1.7% and ≤ 2.3%, respectively.
With the stored frozen samples, SHBG, testosterone,
and estradiol were measured in the laboratory at SRL
(Tokyo, Japan), blinded to cases and controls. Serum
SHBG levels were analyzed with an immunoradiometric
assay; (Siemens Medical Solutions Diagnostics, Los
Angeles, CA, USA), and testosterone levels with an
electro chemiluminescence immuno assay; (Roche Diag-
nostics GmbH, Mannheim, Germany). The intra- and
inter-assay CVs for SHBG in the laboratory at SRL have
been reported to be 1–3% and 7–8% [16], and the lower
limit of detection for SHBG was 1.1 (nmol/L). The intra-
and inter-assay coefficient of variations (CVs) were 1–3%
and 2–3%, and the lower limit of detection was 0.04 ng/mL
for testosterone. Of 600 total testosterone measurements,
undetectable readings (1 control and 1 case among men,
and 4 controls and 3 cases among women) were set to
missing. Free testosterone levels were calculated using the
methods described by Södergård et al. [17] and Vermuelen
et al. [18].
The values for HbA1c were collected as Japan Dia-
betes Society (JDS) values, and then converted to Na-
tional Glycohemoglobin Standardization Program
(NGSP) values using the following conversion formula:
HbA1c (NGSP) = 1.02×HbA1c (JDS)+0.25% [19].
We evaluated the fatty liver condition with the vali-
dated FLI derived from TG levels, BMI, waist circumfer-
ence, and GGT levels as follows: exp[0.953×ln(TG) +
0.139×BMI + 0.718×ln(GGT) + 0.053×waist−15.745]/
(1+exp[0.953×ln(TG) + 0.139×BMI + 0.718×ln(GGT) +
0.053×waist−15.745])×100 [20]. The FLI has a relatively
high accuracy in detecting fatty liver (0.84 [95% CI,
0.81–0.87]) [20] and studies have shown that the FLI is
associated with higher hepatic-related and cardiovascular
disease mortality [21], incidence of diabetes [22], and
insulin resistance, risk of coronary heart disease, and
early atherosclerosis [23].Statistical analysis
We conducted all analyses by sex. Baseline characteris-
tics were compared between case patients and control
subjects using the paired t-test for continuous variables
and the McNemar’s test for categorical variables. Pear-
son correlation coefficients (r) were calculated to evalu-
ate associations between testosterone and SHBG levels,
fasting insulin and glucose levels, HbA1c levels, BMI,
and FLI among controls.
Odds ratios (ORs) and 95% confidence intervals were
calculated according to quartiles based on the joint dis-
tribution of cases and controls by sex; the lowest quartile
was used as the reference. We fitted conditional logistic
regression models to estimate the association between
SHBG and diabetes. In Model 1, we stratified on
matched pairs using conditional logistic regression mod-
els. We further adjusted for smoking status (never, past,
or current), physical activity (rarely/never, 1 to 3 times
per month, 1 to 2 times per week, and more than 3
times per week), history of hypertension, family history
of diabetes, alcohol use (almost none, occasional, or
regular), menopausal status (women only), and BMI
(continuous) (Model 2). To examine the impact of a
fatty liver in the association, we additionally included the
FLI (quartiles) in the model (Model 3). In Model 4, we
further included levels of fasting insulin (quartiles), total
testosterone (quartiles), and SHBG (quartiles) that were
not examined as the primary independent variable. As
sensitivity analyses, we additionally adjusted for total en-
ergy intake (quartiles) but this additional adjustment did
not materially change the estimates. P-values for trend
were computed based on median levels in categories. To
assess nonmultiplicative interactions of testosterone and
SHBG levels with gender, we fitted logistic models with
product terms for each of these interactions, treating the
biomarkers as continuous variables.
To further provide visual representation of the dose–
response curve, we fitted restricted cubic spline models
by including transformed variables of exposure variables
to multiple logistic regression models (with 2 knots at
the 33.3th and 67.7th percentiles) with adjustment for
covariates included in Model 3 [24]. We conducted stat-
istical analyses using SAS (version 9.3; SAS institute,
Cary, NC) and STATA (version 12.0; StataCorp, College
Station, TX).
Results
The baseline characteristics of diabetes cases and
matched-controls by sex are presented in Table 1. In
both men and women, diabetes cases tended to have
higher BMI, waist, HbA1c, fasting glucose levels, fasting
insulin levels, and FLI than controls. Also, cases tended
to have a history of hypertension and dyslipidemia, and
Table 1 Baseline characteristics between participants
with cases of type 2 diabetes and control participants
Characteristics Cases Controls P-values *
Men
No. 215 215
Age (yr) 64.5 ± 6.6 64.5 ± 6.6
BMI (kg/m2) 24.1 ± 2.9 23.4 ± 2.7 0.01
Waist (cm) 87.0 ± 8.2 84.9 ± 7.7 0.006
Alcohol (% ≥ once/wk) 74.0 80.5 0.09










Family history of diabetes
(%)
29.8 13.0 <0.001
HbA1c (%) 6.6 ± 0.9 5.6 ± 0.3 <0.001
Fasting glucose (mg/dL) 128.5 ± 30.9 97.4 ± 6.2 <0.001
Fasting insulin (μIU/mL) 6.3 ± 5.4 4.5 ± 3.7 <0.001
Fatty liver index 38.1 ± 24.0 28.3 ± 19.6 <0.001
C-reactive protein (mg/dL) 0.23 ± 1.04 0.10 ± 0.17 0.07
Sex hormones
SHBG (nmol/L) 72.6 ± 28.3 76.7 ± 28.9 0.12
Total testosterone
(ng/mL)
4.7 ± 1.7 5.4 ± 1.7 <0.001
Free testosterone
(ng/mL)
4.1 ± 1.6 4.5 ± 1.6 <0.002
Women
No. 85 85
Age (yr) 63.2 ± 7.0 63.2 ± 7.0
BMI (kg/m2) 24.0 ± 3.7 21.5 ± 2.6 <0.001
Waist (cm) 85.6 ± 8.9 77.8 ± 8.6 <0.001
Alcohol (% ≥ once/wk) 24.7 20.0 0.45










Menopause (%) 82.4 72.9 0.13
Family history of diabetes
(%)
41.2 17.7 0.002
HbA1c (%) 6.7 ± 1.1 5.7 ± 0.3 <0.001
Fasting glucose (mg/dL) 124.9 ± 31.5 96.0 ± 7.2 <0.001
Fasting insulin (μIU/mL) 6.8 ± 4.7 3.9 ± 2.0 <0.001
Fatty liver index 30.2 ± 23.3 13.6 ± 14.0 <0.001
C-reactive protein (mg/dL) 0.14 ± 0.22 0.06 ± 0.06 0.003
Table 1 Baseline characteristics between participants
with cases of type 2 diabetes and control participants
(Continued)
Sex hormones
SHBG (nmol/L) 79.9 ± 35.9 102.7 ± 32.1 <0.001
Total testosterone
(ng/mL)
0.18 ± 0.10 0.15 ± 0.07 0.06
Free testosterone
(ng/mL)
0.13 ± 0.09 0.09 ± 0.05 <0.001
Abbreviations: SHBG, sex hormone-binding globulin; FLI, fatty liver index.
Data are means ± SD.
* Baseline characteristics were compared between case patients and controls
using the paired t-test for continuous variables and McNemar’s test for
categorical variables.
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lower total testosterone levels than controls, while dia-
betic women tended to have higher C-reactive protein
and lower SHBG levels than controls. In addition, 114
participants with diabetes (78 men and 36 women) were
using anti-diabetic medications and 186 (137 men and
49 women) were not.
The correlation coefficients between testosterone,
SHBG, BMI, FLI, and glycemia among control partici-
pants by sex are shown in Table 2. As a result of the free
testosterone calculation from total testosterone, SHBG,
and albumin levels by the formula of Södergård and
Vermeulen et al. [17,18], free testosterone showed a
strong positive correlation with total testosterone and
a strong inverse correlation with SHBG in both men
and women. In men, total testosterone levels were
positively correlated with SHBG levels and inversely
correlated with BMI, HbA1c, and FLI; free testosterone
levels were inversely correlated with BMI and FLI.
SHBG levels in men were inversely correlated with
BMI and FLI, but not with glycemia. In women, total
testosterone levels were not correlated with SHBG
levels, BMI, fasting insulin, or glycemia, but showed a
positive correlation with FLI; free testosterone levels
were positively correlated with BMI, fasting insulin,
glycemia, and FLI. SHBG levels in women were in-
versely correlated with BMI, HbA1c, fasting insulin,
and FLI.
After multivariable adjustment for age, family his-
tory of diabetes, smoking, physical activity, and BMI
(Table 3; Model 2), SHBG levels were inversely asso-
ciated with diabetes among women (OR comparing
the highest with the lowest quartiles, 0.13 [95% CI,
0.02–0.86]), but not among men (OR, 0.73 [95% CI,
0.38–1.40]). Further adjustment for FLI slightly atte-
nuated the association, but the strong inverse associ-
ation observed in women remained (OR, 0.13 [95%
CI, 0.02–0.96]) (Table 3; Model 3), suggesting that the in-
verse association of SHBG with diabetes is independent of
fatty liver. Adjustment for TG, waist, and GGT in Model 3
Table 2 Correlation coefficients between sex hormones, SHBG, BMI, insulin, glucose, HbA1c, and FLI among control
subjects by sex
Men Total T Free T SHBG BMI Fasting insulin FPG HbA1c
Free T 0.48 (P<0.001)
SHBG 0.61 (P<0.001) −0.37 (P<0.001)
BMI −0.31 (P<0.001) −0.15 (P=0.02) −0.20 (P<0.001)
Fasting Insulin −0.03 (P=0.66) −0.09 (P=0.17) 0.06 (P=0.37) 0.45 (P<0.001)
FPG −0.08 (P=0.22) 0.01 (P=0.84) −0.08 (P=0.24) 0.06 (P=0.35) 0.17 (P=0.02)
HbA1c −0.15 (P=0.03) −0.06 (P=0.34) −0.05 (P=0.45) −0.02 (P=0.77) 0.04 (P=0.59) 0.27 (P<0.001)
FLI −0.36 (P<0.001) −0.14 (P=0.04) −0.26 (P<0.001) 0.75 (P<0.001) 0.43 (P<0.001) 0.13 (P=0.05) −0.06 (P=0.42)
Women Total T Free T SHBG BMI Fasting insulin FPG HbA1c
Free T 0.81 (P<0.001)
SHBG 0.06 (P=0.62) −0.47 (P<0.001)
BMI 0.16 (P=0.17) 0.41 (P<0.001) −0.46 (P<0.001)
Fasting Insulin 0.11 (P=0.33) 0.30 (P=0.01) −0.34 (P=0.002) 0.53 (P<0.001)
FPG 0.16 (P=0.16) 0.19 (P=0.09) −0.16 (P=0.14) 0.14 (P=0.20) 0.45 (P<0.001)
HbA1c 0.19 (P=0.08) 0.26 (P=0.02) −0.25 (P=0.02) 0.13 (P=0.22) 0.26 (P=0.01) 0.46 (P<0.001)
FLI 0.30 (P=0.01) 0.51 (P<0.001) −0.38 (P<0.001) 0.77 (P<0.001) 0.62 (P<0.001) 0.35 (P=0.001) 0.30 (P=0.005)
Abbreviations: Total T, total testosterone; free T, free testosterone; SHBG, sex hormone-binding globulin; BMI, body mass index; FLI, fatty liver index.
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curves clearly indicated that higher SHBG levels were
markedly associated with a reduced chance of having dia-
betes in women, but not in men (Figure 1C and 1D). In
addition, in a subgroup analysis restricted to postmeno-
pausal women, similar patterns were observed. As com-
pared with the lowest quartile of the intake, the adjusted
ORs of diabetes across increasing quartiles were 1.00
(reference), 0.14 (95% CI, 0.01–1.48), 0.20 (95% CI, 0.04–
1.07), and 0.12 (95% CI, 0.01–1.17) (P-value for trend =
0.07)among premenopausal women, however, we were not
able to observe any pattern due to the small sample size
(15 cases and 13 controls). P-value for interaction by sex
was 0.007, indicating the importance of considering the
sex-specific effects of SHBG. An additional adjustment for
fasting insulin and total testosterone levels had little im-
pact on the estimates (Table 3; Model 4).
In contrast, after multivariable adjustment for known
risk factors, total testosterone levels were inversely asso-
ciated with diabetes among men (OR, 0.44 [95% CI,
0.23–0.84]), whereas a strong positive relation was sug-
gested among women, although the estimates were very
imprecise (Table 3; Model 2). Spline curves suggested a
moderate inverse association between total testosterone
and diabetes in men, but not in women (Figure 1A and
1B), suggesting that the total testosterone-diabetes rela-
tion observed among women (Table 3) was a statistically
unstable estimate. The P-value for interaction by sex was
0.29, indicating insufficient evidence to support a sex-
difference in the total testosterone and type 2 diabetes
relation. Further adjustment for FLI (Table 3; Model 3),
and SHBG and insulin levels (Table 3; Model 4) did notmaterially alter the estimates. In addition, we examined
the relation between free testosterone levels and diabetes
by sex. In a manner similar to total testosterone, after
multivariable adjustment for known risk factors (Model
2), free testosterone levels were inversely associated with
diabetes among men (OR, 0.44 [95% CI, 0.23–0.85]), but
the estimates for women were very imprecise (OR, 15.28
[95% CI, 2.25–103.86]) (data not shown). The P-value
for interaction by sex was 0.008. This suggests a sexual-
dimorphism in the relation between free testosterone
and diabetes; however, the effect measure modification
might have been mainly driven by the SHBG-diabetes
relation. Spline curves suggested a moderate inverse as-
sociation between free testosterone and diabetes in men,
but not in women (data not shown).
Discussion
In this well-characterized case–control study in a Japa-
nese population, we identified SHBG levels in women
and total and free testosterone levels in men to be in-
versely associated with diabetes after multivariable ad-
justment for FLI and fasting insulin as well as known
risk factors for diabetes. These findings suggest that
SHBG in women and testosterone in men are not merely
markers of liver function or hyperinsulinemia, adding
support to the notion that SHBG and sex hormones may
play important roles in the development of type 2
diabetes.
The findings for SHBG levels are in general agreement
with previous findings. A systematic review and meta-
analysis showed that SHBG was inversely associated with
Table 3 Odds ratio (95% CI) for type 2 diabetes according to quartiles of sex hormone and SHBG levels by sex
Men Quartiles
Q1 (lowest) Q2 Q3 Q4 (highest) P for trend*
Testosterone (ng/mL)
Median (range) 3.04 (0.06–3.84) 4.42 (3.85–4.88) 5.44 (4.90–6.20) 6.96 (6.21–12.80)
(cases/controls) 69/39 54/55 49/56 43/64
Model 1† 1.00 0.55 (0.31–0.98) 0.48 (0.27–0.84) 0.37 (0.21–0.66) <0.001
Model 2‡ 1.00 0.72 (0.38–1.37) 0.62 (0.32–1.20) 0.44 (0.23–0.84) 0.01
Model 3§ 1.00 0.66 (0.34–1.29) 0.64 (0.33–1.26) 0.45 (0.23–0.89) 0.03
Model 4|| 1.00 0.64 (0.32–1.30) 0.63 (0.29–1.34) 0.40 (0.18–0.88) 0.03
SHBG (nmol/L)
Median (range) 42.1 (16.8–52.4) 62.2 (52.5–72.4) 81.8 (72.5–93.6) 112.0 (93.8–161.0)
(cases/controls) 58/50 55/54 55/52 47/59
Model 1† 1.00 0.87 (0.50–1.51) 0.87 (0.50–1.54) 0.67 (0.38–1.18) 0.17
Model 2‡ 1.00 0.81 (0.43–1.51) 1.04 (0.55–2.00) 0.73 (0.38–1.40) 0.44
Model 3§ 1.00 0.85 (0.44–1.64) 1.15 (0.59–2.24) 0.79 (0.41–1.53) 0.59
Model 4|| 1.00 1.04 (0.52–2.10) 1.55 (0.73–3.27) 1.22 (0.56–2.67) 0.54
Women
Testosterone (ng/mL)
Median (range) 0.08 (0.04–0.10) 0.13 (0.11–0.15) 0.19 (0.16–0.22) 0.27 (0.23–0.48)
(cases/controls) 20/24 19/22 22/21 21/14
Model 1† 1.00 1.09 (0.49–2.47) 1.33 (0.55–3.17) 1.83 (0.76–4.40) 0.17
Model 2‡ 1.00 0.76 (0.22–2.69) 1.05 (0.29–3.81) 1.90 (0.54–6.68) 0.27
Model 3§ 1.00 0.72 (0.20–2.62) 0.97 (0.25–3.79) 2.02 (0.54–7.54) 0.25
Model 4|| 1.00 0.74 (0.13–4.09) 2.82 (0.36–22.10) 9.20 (0.80–105.15) 0.046
SHBG (nmol/L)
Median (range) 49.5 (12.9–60.8) 76.6 (61.3–89.4) 105.0 (89.5–124.0) 139.5 (125.0–163.0)
(cases/controls) 33/10 20/22 20/23 12/30
Model 1† 1.00 0.35 (0.13–0.91) 0.32 (0.13–0.78) 0.15 (0.05–0.40) <0.001
Model 2‡ 1.00 0.17(0.03–0.91) 0.19 (0.05–0.79) 0.12 (0.02–0.86) 0.03
Model 3§ 1.00 0.18 (0.03–0.98) 0.20 (0.05–0.87) 0.13 (0.02–0.96) 0.048
Model 4|| 1.00 0.21 (0.02–2.78) 0.23 (0.03–1.93) 0.03 (0.001–0.86) 0.06
Data are ORs (95% CI). Abbreviations: SHBG, sex hormone-binding globulin; ORs, odds ratios; CI, confidence interval * P-values for trend are based on median
levels in categories. † Model 1: stratified on matched pairs using conditional logistic regression models. ‡ Model 2: further adjusted for smoking status, physical
activity, history of hypertension, family history of diabetes, alcohol use, menopausal status (women only), and BMI. § Model 3: further adjusted for the fatty liver
index (quartiles). || Model 4: further adjusted for levels of fasting insulin (quartiles), testosterone (quartiles), and SHBG (quartiles) that were not examined as the
primary independent variable.
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after adjustment for known risk factors for type 2 dia-
betes and the inverse association was stronger in women
than in men [1]. In addition, previous studies in multi-
ethnic populations have reported that the association
remained consistent across ethnic groups: African-
Americans, Hispanics, and Asians [25,26]. We did not
observe the association in men and the interaction for
gender was statistically significant (P = 0.007). Import-
antly, an earlier study in a largely Hispanic-American
population from the San Antonio Heart Study found
that the inverse association between SHBG and diabetes
risk was strong in pre-menopausal women, weak in post-
menopausal women, and negligible in men [27],suggesting a possible sexual-dimorphism in the associ-
ation. Several studies examined whether the SHBG-
diabetes relation was independent of sex hormones and
reported that the relation remained [25,26].We observed
that further adjustment for total testosterone levels had
little impact on the estimates, suggesting that the
mechanisms whereby SHBG contributes to diabetes de-
velopment may be independent of testosterone [28]. Fur-
ther, we investigated the impact of fatty liver on the
SHBG-diabetes association with the FLI and found that
further adjustment for FLI slightly attenuated the
SHBG-diabetes association, but the association
remained, indicating that SHBG may not merely be a
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Figure 1 The odds ratios of type 2 diabetes from restricted cubic spline models. Abbreviation: SHBG, sex hormone binding globulin.
Restricted cubic spline models with the inclusion of transformed variables in the conditional logistic regression models (with knots at the 33.3th
and 67.7th percentiles) were used to estimate odds ratios (solid curve) with pointwise 95% confidence limits (dashed curves). The median value
(Table 3) in the lowest quartile of each variable was used to estimate odds ratios. Adjustment was performed for matched strata, smoking status,
physical activity, history of hypertension, family history of diabetes, alcohol use, menopausal status (women only), BMI, and the fatty liver index
(quartiles). Panel A shows the results for total testosterone levels among men. Panel B shows the results for total testosterone levels among
women. Panel C shows the results for SHBG levels among men. Panel D shows the results for SHBG levels among women.
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genetic studies provided compelling evidence that genet-
ically determined SHBG levels as well as variants of the
SHBG gene are associated with type 2 diabetes risk [2].
Taken together, these findings support the role of SHBG
in the development of diabetes.
Although the exact mechanisms by which SHBG influ-
ences the diabetes risk remain largely unclear, SHBG
may contribute to the impairment of glucose metabolism
through modulation of sex hormone bioavailability and
direct activation of a specific receptor for SHBG [28].
Compensatory hyperinsulinemia resulting from insulin
resistance has been proposed to be responsible for the
apparent inverse SHBG-diabetes relationship [29]; how-
ever, it has been shown recently that a significant in-
crease rather than decrease occurs in plasma SHBG
levels after initiating insulin treatment in type 2 diabetic
patients [30].Total and free testosterone levels were inversely asso-
ciated with diabetes among men, while a possible posi-
tive association was suggested among women after
adjustment for known risk factors for type 2 diabetes in
our study. These findings are in line with previous stud-
ies. In a systematic review and meta-analysis, Ding et al.
found an inverse association between testosterone and
diabetes in men; they found a positive association be-
tween testosterone and diabetes in women [1]. Growing
evidence in human and rodents supports the roles of an-
drogen in the glucose metabolism. Testosterone replace-
ment resulted in improved glycemic control in
hypogonadal men with type 2 diabetes [31] and andro-
gen receptor knockout male mice manifested insulin re-
sistance and impaired glucose tolerance [12]. Decreased
testosterone levels may contribute to the development of
diabetes by increasing insulin resistance via decreasing
lean mass and increasing fat mass [32]. The inverse
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http://www.cardiab.com/content/11/1/130testosterone-diabetes relation in men remained after
adjusting for BMI and fasting insulin in our study, sug-
gesting that there may be an alternative pathway relating
testosterone and diabetes.
Categorical analyses (Models 1–4) in our study sug-
gested that, in contrast to men, total and free testoster-
one levels appeared to be positively associated with
diabetes in women. The interaction for gender was sig-
nificant for free testosterone (P-value = 0.008), although
this might have been driven by the sex-difference in the
SHBG-diabetes relation. However, the dose–response re-
lation between testosterone levels and diabetes using
cubic spline models indicated that no clear conclusions
can be drawn regarding the testosterone-diabetes rela-
tion among women. Of importance, the total testoster-
one levels among women were far smaller than the
levels among men; the median values of testosterone in
the highest quartile of testosterone levels were 0.27 ng/mL
among women and 6.96 ng/mL among men. This differ-
ence makes it difficult to directly compare the relation of
testosterone with diabetes between men and women. Fur-
ther experimental and observational studies are needed to
better elucidate the sex-specific role of testosterone in the
regulation of glucose metabolism.
Our study has several strengths. First, about 95% of
the participants who did not self-report diabetes under-
went the 75 g oral glucose tolerance test, which mini-
mized the possibility of the inclusion of undiagnosed
diabetic patients in the control group. Second, we
obtained detailed measures of variables, allowing us to
control for a number of potential confounding factors.
Third, the control participants were randomly selected
from the same population that gave rise to the cases
which minimized the selection bias. Nevertheless, some
limitations of the present study merit consideration.
First, we were unable to establish a temporal relationship
between the exposure (i.e., testosterone and SHBG) and
diabetes. In addition, the observed associations may vary
according to the duration of diabetes. Hyperinsulinemia
or insulin resistance typically associated with diabetes
might have resulted in decreased testosterone and SHBG
levels (i.e., reverse causality). Further controlling for fast-
ing insulin levels did not materially alter the results in
our study, but use of sulphonylurea or insulin among
participants with diabetes might have influenced the in-
sulin levels. Therefore, the adjustment for fasting insulin
levels may not have adequately captured the influence of
hyperinsulinemia or insulin resistance. Second, we used
the FLI, a validated surrogate maker for fatty liver, to
examine the impact of fatty liver on the SHBG-diabetes
association. Although this measure has been validated in
independent studies, the FLI is not a perfect measure of
fatty liver. Thus, residual confounding due to misclassifi-
cation of fatty liver cannot be ruled out. Third, we didnot ask women about the use of exogenous estrogen,
which might have confounded the SHBG-diabetes asso-
ciation. The frequency of exogenous estrogen use in
Japan is quite low (≈ 2.8%) [33], so such confounding
would probably have little impact on our estimates. Fi-
nally, measurement errors for the exposures (i.e., testos-
terone and SHBG) might have biased the results.
However, the errors are likely to be nondifferential with
respect to the outcome, because case–control pairs were
matched and laboratory personnel were blinded to case–
control status. Therefore, such misclassifications would
lead to an underestimation of the associations. Because
most women had low testosterone values in our study
and the immune assay in our study may be less sensitive
than other assays, such as liquid chromatography–mass
spectrometry, the possible inaccurate quantification at
low values might have attenuated the association of tes-
tosterone with diabetes in women.
Conclusions
Our findings suggest that SHBG in women and testos-
terone in men are associated with diabetes in a Japanese
population. These findings lend support to the notion
that SHBG and sex hormones may play important roles
in the development of type 2 diabetes.
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